Piramal Pharma LimitedQ2 FY27 Results & Financial Update
Piramal Pharma Limited: Q2 FY27 consolidated results and company financials – revenue ₹2,617.06 Cr, PAT ₹5.03 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Piramal Pharma price & chart
Market price₹195.17
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Piramal Pharma Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Profitability expanded significantly during the quarter, driven by higher capacity utilization, operating leverage, disciplined execution, and sustained cost optimization initiatives. EBITDA reached ₹385 crore, translating to an EBITDA margin of 14.7%, which represents an expansion of over 370 basis points compared to 11.0% in Q2 FY26.
The CDMO division led growth across the network with revenues of ₹1,424 crore, up 36% year-on-year, supported by robust commercial demand across India and North America sites, strong RFP activity, and higher execution efficiency.
The Complex Hospital Generics (CHG) business generated ₹849 crore in revenue, growing 32% year-on-year, bolstered by sustained leadership in inhalation anesthesia and the integration of the Kenalog acquisition as an active growth catalyst.
The Consumer Healthcare (PCH) business recorded revenue of ₹359 crore, reflecting a 13% year-on-year increase, underpinned by strong performance across its core Power Brands and e-commerce channels.
Based on the robust first-half performance and continued business momentum, management upgraded its FY27 outlook, anticipating full-year revenue growth of 19% to 20% alongside higher profitability.
01 · Business model
What does Piramal Pharma do?
Piramal Pharma Limited operates as a leading global pharmaceutical, health, and wellness company, offering a comprehensive portfolio of differentiated products and services across 17 global development and manufacturing facilities and a worldwide distribution network reaching over 100 countries.
The company's operational structure is anchored by three primary business segments: Contract Development and Manufacturing Organization (CDMO) operating under Piramal Pharma Solutions, Complex Hospital Generics (CHG) operating under Piramal Critical Care, and Piramal Consumer Healthcare (PCH) selling over-the-counter consumer and wellness brands.
The CDMO division provides integrated drug discovery, development, and manufacturing services spanning small molecules and biologics, while CHG specializes in hospital-based critical care products such as inhalation anesthetics and intrathecal therapies. PCH focuses on consumer health brands distributed through multi-channel retail and digital platforms.
Piramal Pharma also participates in strategic joint ventures, notably holding a 49% stake in AbbVie Therapeutics India Private Limited, an ophthalmology-focused enterprise in the Indian pharma market where the CDMO business supplies specialized products.
02 · Historical context
What shaped the business before this quarter
The company previously strengthened its biologics and advanced therapy platform by acquiring a controlling stake in Yapan Bio.
The existing distribution agreement with Bayer, which contributed ₹475 crore in FY26 revenue, is scheduled for a natural expiration in December 2026, with an orderly transition jointly managed by both parties.
03 · Financial snapshot
Current quarter vs the available comparable
| Metric | Q2 FY27 | Previous quarter |
|---|---|---|
| Revenue from operations | ₹2,617.06 Cr | ₹2,269.92 Cr |
| Total income | ₹2,652.99 Cr | ₹2,359.33 Cr |
| Profit before tax | ₹63.89 Cr | ₹-27.02 Cr |
| Profit after tax | ₹5.03 Cr | ₹-69.39 Cr |
| EPS | ₹0.04 | ₹-0.52 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
CDMO revenues grew 36% year-on-year to ₹1,424 crore in Q2 FY27 (and 28% in H1 FY27 to ₹2,611 crore), led by strong commercial demand across India and North America sites, a 39% increase in on-patent commercial manufacturing revenues, and a 51% surge in ADC services revenue in H1 FY27.
Complex Hospital Generics revenue advanced 32% year-on-year to ₹849 crore in Q2 FY27 (and 24% in H1 FY27 to ₹1,592 crore), driven by sustained US leadership in Sevoflurane (48% value share) and Intrathecal Baclofen, healthy ex-US Sevoflurane performance, and contributions from the newly integrated Kenalog portfolio.
Consumer Healthcare revenue grew 13% year-on-year to ₹359 crore in Q2 FY27 (and 14% in H1 FY27 to ₹706 crore), propelled by 21% growth in Power Brands and a 32% expansion in e-commerce sales during H1 FY27.
What drove margins
Consolidated EBITDA margin expanded by over 350 basis points year-on-year to 14.7% in Q2 FY27 (13.7% in H1 FY27 compared to 9.8% in H1 FY26), driven by higher facility utilization, operational efficiencies, and improved operating leverage across manufacturing sites.
Margin expansion in the Consumer Healthcare segment was supported by a deliberate focus on portfolio premiumization, emphasizing fewer, higher-potential product launches such as the 'Vizible' range under Lacto Calamine.
Disciplined execution and sustained cost optimization initiatives across all business units helped mitigate inflationary pressures on material and employee expenses.
05 · Demand, customers & order book
Where demand is coming from
Strong request-for-proposal (RFP) activity and healthy order inflows across the network resulted in the addition of 22 new customers during H1 FY27.
The company successfully hosted 110 customer audits during H1 FY27, reflecting sustained customer engagement and confidence in quality systems.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The Phase III development pipeline increased to 28 molecules as of September 2026, compared to 25 molecules in March 2026, alongside the addition of 22 new customers during H1 FY27.
PCH maintained a multi-channel distribution network spanning over 180,000 chemists and cosmetic shops, 13,000+ modern trade outlets, and more than 20 e-commerce platforms.
Geography and market mix
India and North America manufacturing sites spearheaded performance across the CDMO network during the first half of fiscal 2027.
Complex Hospital Generics expanded its footprint by building solid traction in Rest-of-World (RoW) and ex-US markets for inhalation anesthesia alongside its established US market leadership.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The expansion project at Lexington remains on track to add sterile fill-finish capabilities, completing the integrated antibody-drug conjugate (ADC) platform offering.
A new microbiology laboratory was successfully commissioned at the Lexington site during the period.
Projects, capex and execution
Capital work in progress (CWIP), including intangible assets under development (IAUD), stood at ₹1,271 crore as of September 30, 2026, up from ₹1,100 crore as of March 31, 2026, reflecting ongoing investments in network capabilities.
08 · Strategy & new businesses
How the company is trying to change its growth mix
The company continued to scale its advanced offerings, with ADC services revenue growing 51% year-on-year in H1 FY27, backed by the integration of Yapan Bio and expanded specialized manufacturing infrastructure.
09 · Reported developments
What changed operationally
The company successfully completed 12 regulatory inspections and 110 customer audits during H1 FY27, maintaining its track record of zero Official Action Indicated (OAI) classifications across US FDA inspections.
10 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Net working capital stood at ₹2,260 crore as of September 30, 2026, compared to ₹2,081 crore as of March 31, 2026.
Capital allocation & funding
Net debt stood at ₹4,859 crore as of September 30, 2026, compared to ₹4,164 crore as of March 31, 2026, while total equity remained stable at ₹8,165 crore.
11 · Key Q&A
The quarter, answered directly
What does Piramal Pharma do?
Piramal Pharma Limited operates as a leading global pharmaceutical, health, and wellness company, offering a comprehensive portfolio of differentiated products and services across 17 global development and manufacturing facilities and a worldwide distribution network reaching over 100 countries.
What is the clearest takeaway from Q2 FY27?
Profitability expanded significantly during the quarter, driven by higher capacity utilization, operating leverage, disciplined execution, and sustained cost optimization initiatives. EBITDA reached ₹385 crore, translating to an EBITDA margin of 14.7%, which represents an expansion of over 370 basis points compared to 11.0% in Q2 FY26.
What drove revenue or demand?
CDMO revenues grew 36% year-on-year to ₹1,424 crore in Q2 FY27 (and 28% in H1 FY27 to ₹2,611 crore), led by strong commercial demand across India and North America sites, a 39% increase in on-patent commercial manufacturing revenues, and a 51% surge in ADC services revenue in H1 FY27.
What mattered most for margins or profitability?
Consolidated EBITDA margin expanded by over 350 basis points year-on-year to 14.7% in Q2 FY27 (13.7% in H1 FY27 compared to 9.8% in H1 FY26), driven by higher facility utilization, operational efficiencies, and improved operating leverage across manufacturing sites.
What changed operationally beyond the headline numbers?
The expansion project at Lexington remains on track to add sterile fill-finish capabilities, completing the integrated antibody-drug conjugate (ADC) platform offering.
What should the next disclosure help confirm?
Monitor performance delivery in H2 FY27, which is traditionally stronger than H1, against the upgraded annual revenue growth guidance of 19% to 20%.
12 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
13 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
H2 FY27 Execution and Seasonality: Monitor performance delivery in H2 FY27, which is traditionally stronger than H1, against the upgraded annual revenue growth guidance of 19% to 20%.
- 02
Lexington Facility Milestones: Track the commissioning progress of the sterile fill-finish expansion at the Lexington site and its impact on integrated ADC service delivery.
- 03
Bayer Distribution Transition: Observe the execution of the field-force and operational transition ahead of the natural expiration of the Bayer distribution agreement in December 2026.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.